News
03-18-2010, 09:51 PM
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.
More... (http://www.news-medical.net/news/20100319/ASCO-Scientific-Program-2010-Provectus-Pharmaceuticals-Phase-2-data-on-PV-10-accepted-for-presentation.aspx)
More... (http://www.news-medical.net/news/20100319/ASCO-Scientific-Program-2010-Provectus-Pharmaceuticals-Phase-2-data-on-PV-10-accepted-for-presentation.aspx)